quarter highlight strong cost synergi
reiter buy rate strong
book revenu profit metric least met exceed
estim view set acceler organ growth
ahead schedul cost synergi importantli see evid
quintiles/im merger success far seen acceler
demand nextgen cro offer quarter
health end-market fundament manag execut at/abov plan
stay buy-rat
evid support merger thesi segment book
acceler ttm book y/i particular strength nextgen
deal book view book strength ytd
strong end-market support acceler revenu least
also manag note ahead schedul merger
cost synergi exit target may fulli achiev
target note manag initi expect cost synergi
back-end weight
orchestr custom engag oce build momentum
recal oce launch late revamp commerci platform
integr market access medic affair applic among
other sinc launch competit deal includ
one roch view momentum particularli time given
substanti replac cycl larg pharma next
month success win pharma client
think would translat modest revenu acceler technolog
analyt segment start
earli commentari current fx rate manag expect
headwind guidanc mid-point despit fx headwind
currenc growth ytd
model tweak initi estim rais ep penni
lower estim two penni chang
result small reduct revenu fx headwind sg
faster cost cut estim year model total revenu
growth acceler ebitda
margin expans result ep
initi guidanc
sg revenu
tr target
revenu depict prior year
adjust account rule
consensu estim may blend
account rule may compar strh
page
share upsid current strh factsetstrh scenariovaluationnot model scenario estim ep includ stock-bas comp compar peer match pro forma report ep model ia hold inc
page
sandi draper statement dollar y/i total gross depreci restructur merger impair oper fit incl restruc net interest expens incom incom incom tax tax equiti unconsolid equiti earn unconsolid net net loss incom attribut non-controlling net incom attribut dilut dilut share forma adjust net adj pre-tax tax non-gaap net non-gaap ep onward recast growth forma adjust ebitdaadjust ebitda onward recast margin robinson humphrey research estimatestick iqva
iqvia largest cro revenu oper countri employe
compani found headquart durham nc compani formerli quintil
merg im health combin entiti iqvia oper three segment commerci
solut data technolog drive real world evid use life sceinc client clinic
trial integr healthcar servic contract sale compris
respect sale iqvia first went public taken privat privat equiti
went public acquir im health
buy rate base view ebitda growth exceed revenu growth due
oper leverag cost synergi recognit expect manag reinforc oper
perform share repurchas expect contribut mid-teen ep growth
also think acquir im busi may benefit multipl expans mid-cap peer
technolog servic space given acquisit im
valuat risk
pt assign probabl low case price-to-earnings stock mid case
price-to-earnings stock high case price-to-earnings stock pt impli
price-to-earnings multipl ep estim modestli ahead impli consensu price-to-earnings
justifi expect repurchas effort think contempl street well
valuat consider use broader peer group
risk rate price target
continu cancel late stage busi net book bill remain target
merger synergi fail materi custom attrit due im merger
sandi draper herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
